<DOC>
	<DOC>NCT01409486</DOC>
	<brief_summary>The aim of the study is: to develop a comprehensive biochemical assay for detection of Pompe disease (glycogen storage disease type II), to be implemented in the Newborn screening program among the Israeli population.</brief_summary>
	<brief_title>Screening for Early Detection and Prevention of Pompe Disease in Israel Using Tandem Mass Spectrometry</brief_title>
	<detailed_description />
	<mesh_term>Glycogen Storage Disease Type II</mesh_term>
	<criteria>New born babies born during the study period Premature babies</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>7 Days</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Pompe disease</keyword>
	<keyword>Alpha glucosidase</keyword>
	<keyword>Newborn screening</keyword>
	<keyword>Tandem Mass Spectrometry (LC-MS-MS)</keyword>
	<keyword>The study aims:</keyword>
	<keyword>To establish the control mean values of alpha glucosidase activity in Dry blood spots of Newborn babies from Israel.</keyword>
	<keyword>To include the alpha glucosidase assay in the newborn screening program in Israel</keyword>
</DOC>